Characterization of TCS11 in Streptococcus pneumoniae
- Institution
- ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN
- Principal investigator
- Jason W. Rosch
- Funding
- $221K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
Summary A fundamental aspect of the success of Streptococcus pneumoniae as a human pathogen is the ability to successfully transmit and infect new hosts. The mechanisms underlying transmission are complex, with both bacterial and host factors playing important roles. It would be expected the capacity is sense and response to the dynamic environment of the mammalian host is critical for transmission, however the regulation underscoring this process remains poorly understood. We hypothesize transmission is controlled via a specific, uncharacterized two- component regulatory system (TCS11). This TCS has atypical operon structure for pneumococcal TCSs, whereby two small hypothetical proteins and a putative transporter are in the same operon and co-transcribed with TCS11. Preliminary data suggests is this operon is in fact a TCS coupled to a bacteriocin secretion system that facilitates transmission via targeting the resident bacterial flora, enabling pneumococcal transmission. We hypothesize that TCS11 mediates pneumococcal transmission via coordination of transmission factor gene expression coupled with bacteriocin production to effectively compete against the respiratory microbiota at the initial stages of epithelial colonization.
Research team
- Elisa B H MargolisPI
- Jason W. RoschPI
LOADING MOONBASE SCORE
Questions for ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · ST. Jude Children'S Research HospitalNot yet scored
Trivalent Live Attenuated Vaccines for Bacterial Acute Otitis Media
Jason W. Rosch · $221K · 2024–2026
- NIH · ST. Jude Children'S Research HospitalNot yet scored
Consequences of Direct Viral-Bacterial Interactions
Jason W. Rosch · $487K · 2022–2026
- NIH · Boston Children'S HospitalNot yet scored
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.
Jason W. Rosch · $771K · 2022–2026